Daraxonrasib Shows Activity in Previously Treated RAS-Mutated Pancreatic Cancer

Targeting the Oncogenic Driver in Pancreatic Adenocarcinoma

Pancreatic ductal adenocarcinoma remains a leading cause of cancer-related mortality because standard cytotoxic chemotherapy regimens offer only limited survival improvements [1, 2]. Although activating mutations in the KRAS oncogene drive more than 90 percent of these tumors, the protein was historically viewed as an inaccessible therapeutic target [3, 4]. Recent clinical successes in targeting the inactive state of the KRAS G12C variant provided a proof of concept for precision oncology, yet this specific mutation represents only a small subset of the total patient population [2, 4]. Clinicians require therapeutic options that address the diverse array of RAS mutations encountered in practice, including the common G12D and G12V variants [5, 6]. A recent study evaluates a strategy that targets the active, guanosine triphosphate-bound state of both mutant and wild-type RAS isoforms, a mechanism known as RAS(ON) multiselective inhibition [7, 8]. This investigation examines the safety and clinical activity of this targeted approach in patients with previously treated disease, potentially offering a new therapeutic avenue for a notoriously difficult-to-treat malignancy.

Study Design and Dose Escalation

To evaluate the safety and efficacy of daraxonrasib in patients with advanced solid tumors harboring activating RAS mutations, researchers conducted a phase 1-2 study (ClinicalTrials.gov number NCT05379985). This specific report focuses on a cohort of 168 patients with previously treated RAS-mutated pancreatic ductal adenocarcinoma, a population that typically faces limited options after the failure of initial chemotherapy. The investigation sought to determine the clinical utility of targeting the active state of the RAS protein across various mutation types. During the dose-escalation phase, patients received daraxonrasib orally once daily at doses ranging from 10 to 400 mg. After evaluating the clinical data, the researchers selected 300 mg as the dose for future phase 3 trials. The primary endpoint of the study was safety, while secondary endpoints included antitumor activity and pharmacokinetics (the assessment of how the drug is absorbed, distributed, and cleared by the body). By establishing these parameters, the study aimed to define the therapeutic window for this multiselective inhibitor in a heavily pretreated oncologic population.

Safety Profile and Treatment-Related Adverse Events

In the cohort of 168 patients with previously treated pancreatic ductal adenocarcinoma who received daraxonrasib at a dose of 300 mg or less, the safety analysis revealed a high frequency of low-grade toxicities. Treatment-related adverse events of any grade occurred in 96% of these patients, indicating that nearly all participants experienced some level of drug-related effect. However, the majority of these events were manageable in a clinical setting, as treatment-related adverse events of grade 3 or higher were reported in 30% of the 168 patients. This distinction between the high overall incidence and the lower rate of severe toxicities is critical for clinicians when counseling patients on the expected tolerability of this oral regimen. The specific toxicity profile was characterized primarily by gastrointestinal and dermatologic effects. Adverse events occurring in at least 10% of patients included rash, diarrhea, nausea, stomatitis or mucositis (inflammation of the mucous membranes lining the mouth and digestive tract), vomiting, and fatigue. These side effects are consistent with the inhibition of RAS signaling in healthy epithelial tissues. For the practicing oncologist, the prevalence of stomatitis and diarrhea necessitates proactive monitoring and supportive care to maintain dose intensity. Despite the 30% rate of grade 3 or higher events, the safety profile remained consistent with the mechanism of action of a multiselective RAS inhibitor, providing a defined therapeutic window for the selected 300 mg phase 3 dose.

Clinical Activity Across RAS Mutation Subgroups

Because activating RAS mutations occur in more than 90% of pancreatic ductal adenocarcinoma tumors, the development of effective inhibitors targeting these drivers is a clinical priority. Daraxonrasib functions as an oral RAS(ON) multiselective inhibitor, a mechanism designed to target both mutant and wild-type RAS when they are in their active, guanosine triphosphate-bound state. This approach allows the agent to address a broad spectrum of RAS alterations that typically drive tumor progression. In a specific subgroup of 26 patients with RAS G12 mutations who received daraxonrasib at the 300 mg dose as second-line therapy, the researchers reported an objective response rate of 35% (95% CI, 17 to 56). The durability of these responses was evidenced by a median duration of response of 8.2 months (95% CI, 3.8 to not evaluable), while the median progression-free survival reached 8.5 months and the median overall survival was 13.1 months. The clinical activity of daraxonrasib extended to a broader cohort of 38 patients with RAS G12, G13, or Q61 mutations. In this group, the objective response rate was 29% (95% CI, 15 to 46), with a median duration of response of 8.2 months (95% CI, 3.8 to 8.8). Although the response rate was slightly lower than in the G12-specific subgroup, the survival metrics remained robust; the median progression-free survival was 8.1 months and the median overall survival reached 15.6 months. For clinicians managing advanced pancreatic ductal adenocarcinoma, these data suggest that daraxonrasib provides a targeted therapeutic option for patients whose tumors harbor RAS mutations and who have progressed on initial treatment lines. The consistency of the duration of response across different mutation types indicates that the multiselective inhibition of active RAS may offer a sustained therapeutic effect in a disease traditionally characterized by rapid progression and limited salvage options.

References

1. Shenoy A, Yousif A, Hussain MD. Recent Advances and Challenges in the Treatment of Advanced Pancreatic Cancer: An Update on Completed and Ongoing Clinical Trials. Cancers. 2025. doi:10.3390/cancers17081319

2. Fivaz M, Bornand A, Corro C, Koessler T, Genoud V. Actionable mutations in pancreatic cancer: where targeted therapies are making a difference.. BMJ open gastroenterology. 2025. doi:10.1136/bmjgast-2025-001925

3. Rozengurt E, Eibl G. Pancreatic cancer: molecular pathogenesis and emerging therapeutic strategies. Signal Transduction and Targeted Therapy. 2026. doi:10.1038/s41392-025-02499-y

4. Drizyte‐Miller K, Talabi T, Somasundaram A, Cox AD, Der CJ. KRAS: the Achilles’ heel of pancreas cancer biology. Journal of Clinical Investigation. 2025. doi:10.1172/jci191939

5. Wolpin B, Wainberg Z, Garrido-Laguna I, et al. Trial in progress: RASolute 302—A phase 3, multicenter, global, open-label, randomized study of daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor, versus standard of care chemotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology. 2025. doi:10.1200/jco.2025.43.16_suppl.tps4230

6. Aronchik I, Kar S, Zhuang Y, et al. Abstract A081: Resistance Mechanisms to Monotherapy RAS(ON) Multi-Selective Inhibitor Daraxonrasib (RMC-6236) in RAS Mutant PDAC Inform Therapeutic Combination Strategies. Molecular Cancer Therapeutics. 2025. doi:10.1158/1535-7163.targ-25-a081

7. Wolpin BM, Park W, Garrido-Laguna I, et al. Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer.. The New England journal of medicine. 2026. doi:10.1056/NEJMoa2505783

8. Moore J, Bargenquast T, Halder TG, et al. Abstract 6497: Synergistic disruption of KRAS and FAK pathways: A preclinical pipeline for PDAC therapy optimization. Cancer Research. 2026. doi:10.1158/1538-7445.am2026-6497